Hans Krankenberg

Hans Krankenberg

Auto-generated profile, based on publicly available information

Hans Krankenberg

Department of Vascular Medicine, Sana-Kliniken Oberfranken GmbH, Coburg, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2011 in Angiology
Verified
Journal Article
Closed access
SSSebastian Sixt
Sebastian Sixt
ARAljoscha Rastan
Aljoscha Rastan
DSDierk Scheinert
Dierk Scheinert
HKHans Krankenberg
Hans Krankenberg
HSHermann Steinkamp
Hermann Steinkamp
TZThomas Zeller
Thomas Zeller
The present study was carried out to provide information about outcome of the Jetstream atherectomy device for treatment of infrainguinal arteries. From February 2006 to February 2007, 172 patients with Rutherford class 1 to 5 lower limb ischemia were enrolled at 9 study sites. The endpoints were evaluation of quality of life according to the walking impairment questionnaire (WIQ) besides technical parameters. In the total study cohort, the WIQ scale maintained improved up to 12-month follow-up. Furthermore, target lesion revascularization rate was 26% (42/162), ankle-brachial index (ABI) increased from 0.59 ± 0.21 at baseline to 0.82 ± 0.27 ( P < 0.05), and mean Rutherford class dropped from 3.0 ± 0.9 at baseline to 1.5 ± 1.3 at 1 year ( P < .05). The results of this prospective, multicenter, clinical study demonstrate that the Jetstream atherectomy device is a potential treatment alternative for the endovascular management to improve clinical outcome in patients with peripheral arterial occlusive disease.

1 July 2024 in Vasa
Verified
Journal Article
Closed access
JPJohannes Pampel
Johannes Pampel
CMConni McCarthy
Conni McCarthy
HKHans Krankenberg
Hans Krankenberg
GDGudrun Dannberg
Gudrun Dannberg
PSP. Christian Schulze
P. Christian Schulze
MTMarcus Thieme
Marcus Thieme
Summary: Background: The purpose was to analyze the use of classical music to reduce procedure-related anxiety while conducting percutaneous transluminal angioplasty in patients with peripheral artery disease. Patients and methods: A total of 155 patients were analyzed in this single center randomized controlled trial. Procedure-related anxiety was assessed by a numerical rating scale (NRS, 0–10) and by recording of physiological parameters at three different points in time. A survey was conducted after the intervention. Results: This study showed that the patients listened to music overcame their procedure-related anxiety more quickly than the patients in the control group. The NRS at second timepoint was significantly reduced in intervention group compared to control group (p<0.01; r=0.2). Most participants stated that they would like to listen to music during possible future interventions. Conclusions: Classical music during endovascular interventions reduced procedure-related anxiety measured as greater reduction in NRS values in intervention group as well as in results of questionnaire performed post procedurally in PAD patients.

1 July 2022 in Vasa
Verified
Journal Article
Closed access
FVFelix Voll
Felix Voll
FWFlorian Wolf
Florian Wolf
MIMaja Ingwersen
Maja Ingwersen
CKChristian M. Kinstner
Christian M. Kinstner
SKSebastian Kufner
Sebastian Kufner
SCSalvatore Cassese
Salvatore Cassese
Summary: Background: The influence of diabetes mellitus (DM) on recurrent in-stent restenosis (ISR) of femoropopliteal arteries remains understudied. We investigated whether DM has an impact on rec...

7 January 2022 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
MTMarcus Thieme
Marcus Thieme
JAJarwed Arjumand
Jarwed Arjumand
MSMarkus Spanagel
Markus Spanagel
GTGunnar Tepe
Gunnar Tepe
EBErwin Blessing
Erwin Blessing
HKHans Krankenberg
Hans Krankenberg
Purpose: This postmarketing surveillance study aimed to assess effectiveness and safety of a peripheral self-expanding stent with high torsional strength (POLARIS stent) for the treatment of de novo superficial femoral artery (SFA) lesions in the routine clinical practice. Materials and Methods: Consecutive patients with symptomatic de novo SFA occlusive disease who underwent POLARIS stent implantation were enrolled into the prospective, multicenter, observational postmarket surveillance study. Primary outcome measure was freedom from clinically driven target lesion revascularization (cdTLR) at 12 months. Main secondary outcomes were procedural success, primary clinical improvement, and freedom from major adverse cardiovascular and limb events (MACLE) throughout 24 months. Results: A total of 199 participants (70±11 years, 70.4% men) were included in the study at 9 German sites from December 2014 to August 2018. Half of them (52.6%) were current smokers, 37.6% had diabetes, and 25.0% were obese. Most participants suffered from intermittent claudication (88.4%). Mean lesion length was 98±83 mm, 43.5% of lesions were occluded, and 27.3% were severely calcified. Freedom from 12 months cdTLR was 94.4% (95% confidence interval [CI], 90.6–98.2). At 24 months, freedom from cdTLR was 88.7% (95% CI, 83.0–94.4). Procedural success was achieved in 96.2% of participants. Primary clinical improvement occurred in 87.5% and 85.4% of participants at 12 and 24 months, respectively. Freedom from MACLE was 94.8% (95% CI, 91.4–98.1) and 93.8% (95% CI, 89.9–97.6) at 12 and 24 months, respectively. Conclusions: Treatment of SFA occlusive disease in a real-world setting using the POLARIS stent with high bidirectional torsional strength is efficacious and does not raise any safety concern in the medium term. The study is registered with ClinicalTrials.gov (Identifier: NCT02307292).

1 May 2026 in Vasa
Verified
Journal Article
Closed access
CFCharlott Fuß
Charlott Fuß
HKHans Krankenberg
Hans Krankenberg
PAPawel Aftanski
Pawel Aftanski
PSP. Christian Schulze
P. Christian Schulze
MTMarcus Thieme
Marcus Thieme
Summary: Background: Infrapopliteal lesions account for one-third of peripheral artery disease (PAD) cases; however, its endovascular treatment data are insufficient. Although paclitaxel-coated drug-coated-balloons (DCBs) reduce restenosis and the need for re-interventions in femoropopliteal arteries, their effectiveness in below-the-knee (BTK) vessels is uncertain. This study evaluated the real-world effectiveness and safety of paclitaxel-coated DCBs in BTK vessels. Patients and methods: This retrospective single-centre study included consecutive patients treated with paclitaxel-coated Luminor™ DCB in BTK arteries between August 2017 and March 2022. The follow-up extended to 60 months. Data were retrieved from archives, phone interviews and physician inquiries. Results: Seventy-nine patients (65.5% male; mean age 74.9±9.2 years) underwent 84 interventions with 114 DCBs. The overall and treated lesion lengths averaged 102.1±80.3 and 117.2±75.5 mm, respectively. The median preoperative Rutherford score was 5 [interquartile range (IQR), 5–5; n=80]. The ankle–brachial index (ABI, 0.8±0.4–1.0±0.2, P=.002) and toe–brachial index (TBI, 0.3±0.3–0.6±0.2, P=.039) significantly improved post-intervention. The wound, ischaemia and foot infection score components showed median value reductions from the pre- to the postinterventional assessment: wound, from 1 (IQR, 1–2) to 1 (0–1); ischaemia, from 1 (IQR, 0–2) to 0 (0–1); and foot infection, from 1 (IQR, 0–2) to 0 (0–1). Kaplan–Meier analysis revealed 25 major adverse limb events, 17 re-interventions, 15 major adverse cardiac events, and 8 major amputation events over 5 years. Re-intervention-free survival was lower in men than in women (P=.036). Diabetic status or renal function was not significantly different. The 3-year mortality was 46.4%. Conclusions: This study highlights the clinical benefit of infrapopliteal paclitaxel-coated DCBs in real-world patients. ABI and TBI improvements reflect ischaemia relief. Wound-healing trends suggest reduced ischaemia and infection within 3 days, but requires longer follow-up. High mortality rates emphasise the effect of comorbidities and multidisciplinary care requirements.